NGF and blindness (disorder): A randomized double-blind phase II clinical trial, aimed at testing the vision functions in 18 patients aged 2–23 years with stable disease and severe blindness caused by glioma, has proven that ocular instillation of NGF protects the optic pathway glioma-related visual impairment in the absence of any apparent side effects (Falsini et al., 2016a).